Anti-IKB alpha (phospho S32) antibody [EPR3148]
- 20ul selling size
- RabMAb
- Recombinant
- What is this?
5
(1 Review)
|
(70 Publications)
Rabbit Recombinant Monoclonal IKB alpha phospho S32 antibody. Suitable for IP, Dot, WB and reacts with Human, Mouse, Rat, Synthetic peptide samples. Cited in 70 publications.
View Alternative Names
IKBA, MAD3, NFKBI, NFKBIA, NF-kappa-B inhibitor alpha, I-kappa-B-alpha, Major histocompatibility complex enhancer-binding protein MAD3, IkB-alpha, IkappaBalpha
- IP
Unknown
Immunoprecipitation - Anti-IKB alpha (phospho S32) antibody [EPR3148] (AB92700)
Purified ab92700 at 1 : 20 dilution (1μg) immunoprecipitating IKB alpha in HeLa treated with 20ng/mL TNF-alpha for 60 minutes whole cell lysate.
Lane 1 (input) : HeLa (Human cervix adenocarcinoma epithelial cell) treated with 20ng/mL TNF-alpha for 60 minutes whole cell lysate 10μg.
Lane 2 (+) : ab92700 + HeLa treated with 20ng/mL TNF-alpha for 60 minutes whole cell lysate.
Lane 3 (-) : Rabbit monoclonal IgG (ab172730) instead of ab92700 in HeLa treated with 20ng/mL TNF-alpha for 60 minutes whole cell lysate.
Blocking Buffer and concentration : 5% NFDM/TBST.
Diluting buffer and concentration : 5% NFDM/TBST.
Observed band size : 36 kDa
All lanes:
Immunoprecipitation - Anti-IKB alpha (phospho S32) antibody [EPR3148] (ab92700)
Predicted band size: 35 kDa
false
- WB
Unknown
Western blot - Anti-IKB alpha (phospho S32) antibody [EPR3148] (AB92700)
Blocking/Diluting buffer : 5% NFDM/TBST
All lanes:
Western blot - Anti-IKB alpha (phospho S32) antibody [EPR3148] (ab92700) at 1/1000 dilution
Lane 1:
MCF7 (Human breast adenocarcinoma epithelial cell) whole cell lysate at 20 µg
Lane 2:
MCF7 (Human breast adenocarcinoma epithelial cell) treated with 20 ng/mL TNF-alpha for 8 hours whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 35 kDa
Observed band size: 36 kDa
false
- WB
Lab
Western blot - Anti-IKB alpha (phospho S32) antibody [EPR3148] (AB92700)
Blocking/Diluting buffer and concentration 5% NFDM/TBST
All lanes:
Western blot - Anti-IKB alpha (phospho S32) antibody [EPR3148] (ab92700) at 1/500 dilution
Lane 1:
HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysates at 15 µg
Lane 2:
HeLa (Human cervix adenocarcinoma epithelial cell) treated with TNF-α at 20 ng/mL for 5 minutes. Whole cell lysates at 15 µg
Lane 3:
HeLa treated with TNF-α at 20 ng/mL for 5 minutes. Whole cell lysates. Then the membrane was incubated with phosphatase. at 15 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 35 kDa
Observed band size: 36 kDa
false
Exposure time: 3min
- WB
Unknown
Western blot - Anti-IKB alpha (phospho S32) antibody [EPR3148] (AB92700)
Blocking/Diluting buffer : 5% NFDM/TBST
All lanes:
Western blot - Anti-IKB alpha (phospho S32) antibody [EPR3148] (ab92700) at 1/1000 dilution
Lane 1:
HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate at 15 µg
Lane 2:
HeLa (Human cervix adenocarcinoma epithelial cell) treated with 20 ng/mL TNF-alpha for 5 minutes whole cell lysate at 15 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 35 kDa
Observed band size: 36 kDa
false
- WB
Supplier Data
Western blot - Anti-IKB alpha (phospho S32) antibody [EPR3148] (AB92700)
Blocking/Diluting buffer and concentration : 5% NFDM/TBST.
All lanes:
Western blot - Anti-IKB alpha (phospho S32) antibody [EPR3148] (ab92700) at 1/1000 dilution
Lane 1:
Untreated Raw264.7 (Mouse Abelson murine leukemia virus-induced tumor macrophage) whole cell lysate at 20 µg
Lane 2:
Raw264.7 (Mouse Abelson murine leukemia virus-induced tumor macrophage) treated with 50 ng/mL TNF-a and 300 ng/ml BFA for 24 hours whole cell lysate at 20 µg
Lane 3:
Raw264.7 (Mouse Abelson murine leukemia virus-induced tumor macrophage) treated with 50 ng/mL TNF-a and 300 ng/ml BFA for 24 hours whole cell lysate.Then the membrane was incubated with alkaline phosphatase at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 35 kDa
Observed band size: 36 kDa
false
Exposure time: 180s
- WB
Supplier Data
Western blot - Anti-IKB alpha (phospho S32) antibody [EPR3148] (AB92700)
Blocking/Diluting buffer and concentration : 5% NFDM/TBST.
All lanes:
Western blot - Anti-IKB alpha (phospho S32) antibody [EPR3148] (ab92700) at 1/1000 dilution
Lane 1:
Untreated C6 (Rat glial tumor glial cell) whole cell lysate at 20 µg
Lane 2:
C6 (Rat glial tumor glial cell) treated with 100 ng/mL Calyculin A for 30 minutes whole cell lysate at 20 µg
Lane 3:
C6 (Rat glial tumor glial cell) treated with 100 ng/mL Calyculin A for 30 minutes whole cell lysate. Then the membrane was incubated with alkaline phosphatase at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 35 kDa
Observed band size: 36 kDa
false
Exposure time: 20s
- Dot
Unknown
Dot Blot - Anti-IKB alpha (phospho S32) antibody [EPR3148] (AB92700)
Dot blot analysis of IKB alpha (phospho S32) phospho peptide (Lane 1) and IKB alpha non-phospho peptide (Lane 2) labeling IKB alpha (phospho S32) with unpurified ab92700 at a dilution of 1/1000. ab97051 (Peroxidase conjugated goat anti-rabbit IgG) (H+L) at 1/10000 was used as the secondary antibody.
Blocking and diluting buffer : 5% NFDM/TBST.
Exposure time : 3 minutes.
- WB
CiteAb
Western blot - Anti-IKB alpha (phospho S32) antibody [EPR3148] (AB92700)
Western Blotting using Anti-IKB alpha (phospho S32) antibody [EPR3148], ab92700. Publication image from Omer, A. et al., 2020, Nat Commun, 33020468. Legend direct from paper.
The G3BP1 inhibitor, EGCG, recapitulates SASP inhibition associated with G3BP1 loss.a (left) Cell lysates from proliferative and 8-day post-ionizing radiation (+IR) WI-38 cells treated or not with EGCG (40 µM) were subjected to western blot analysis against indicated proteins. (right) Quantifications represent a mean of relative protein levels from three independent experiments ± s.e.m (two-way ANOVA, Fisher’s LSD). b RNA was extracted from cells during proliferative stage (PRO) and 8-day post-ionizing radiation (+IR) from WI-38 cells treated with or without (NT) increasing concentrations of EGCG (10, 20, and 40 µM) and assayed by RT-qPCR using primers against the indicated mRNAs. The data are relative to PRO cells and are a mean of three independent experiments ± s.e.m (one-way ANOVA, Fisher’s LSD). c Conditioned media from proliferative (PRO) cells and 8-day post-ionizing radiation (SEN) WI-38 cells treated with or without 40 µM EGCG. The heatmap indicates the fold change in comparison to the control PRO, SEN, and SEN treated with 40 µM EGCG. Relative expression levels per replicate and average fold change differences are shown as indicated in heatmap. The data are representative of three independent experiments. d RNA was extracted from cells treated with siRNA targeting G3BP1 (siG3BP1) or scrambled control (siCTL) during proliferative stage (PRO) and 8-day post-ionizing radiation (+IR) from WI-38 cells in the presence or absence (NT) of EGCG (40µM). RT-qPCR was then performed using primers against indicated mRNAs. The data are a mean of three independent experiments ± s.e.m (two-way ANOVA, Fisher’s LSD, exact <0.001 p-values from left to right : (top) 0.0001, 0.0001, 0.0001, 0.0011, (bottom) 0.0001, 0.0001, 0.0001, 0.0004, 0.0001, 0.0001). Source Data for panels (a), (b), and (d) are provided in the Source Data File. Raw data for (c) is provided in Supplementary Data 3.
false
Related conjugates and formulations (1)
-
Anti-IKB alpha (phospho S32) antibody [EPR3148] - BSA and Azide free
Reactivity data
Product details
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (70)
Recent publications for all applications. Explore the full list and refine your search
Frontiers in molecular neuroscience 18:1596649 PubMed40980341
2025
Applications
Unspecified application
Species
Unspecified reactive species
Integrative cancer therapies 24:15347354251375464 PubMed40958203
2025
Applications
Unspecified application
Species
Unspecified reactive species
Allergologia et immunopathologia 53:36-44 PubMed40923418
2025
Applications
Unspecified application
Species
Unspecified reactive species
CNS neuroscience & therapeutics 31:e70606 PubMed40916543
2025
Applications
Unspecified application
Species
Unspecified reactive species
Research (Washington, D.C.) 8:0759 PubMed40607322
2025
Applications
Unspecified application
Species
Unspecified reactive species
Urolithiasis 53:134 PubMed40601009
2025
Applications
Unspecified application
Species
Unspecified reactive species
Chemical biology & drug design 105:e70068 PubMed40110966
2025
Applications
Unspecified application
Species
Unspecified reactive species
Biomolecules & biomedicine 25:1571-1580 PubMed39757930
2025
Applications
Unspecified application
Species
Unspecified reactive species
EMBO reports 26:690-719 PubMed39702801
2024
Applications
Unspecified application
Species
Unspecified reactive species
Molecular medicine (Cambridge, Mass.) 30:220 PubMed39563244
2024
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com